Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT00478426 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Endometrioid Adenocarcinoma
Endometrial Serous Adenocarcinoma
Recurrent Uterine Corpus Carcinoma
Stage IVA Uterine Corpus Cancer AJCC v7
Stage IVB Uterine Corpus Cancer AJCC v7
Uterine Carcinosarcoma
Uterine Corpus Carcinosarcoma

Interventions

DRUG: Sunitinib Malate

Sponsor

National Cancer Institute (NCI)